Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 4:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 68 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Manic-Depressive Psychosis Clear all
Active, not recruiting Not applicable Interventional

EPI-MINN: Targeting Cognition and Motivation - National

NCT05877716
View directory record Official record
Conditions
Psychosis, Psychosis Nos/Other, Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder, Prodromal Schizophrenia, Schizophrenia Spectrum and Other Psychotic Disorders, Schizophreniform Disorders, Major Depression With Psychotic Features, Unspecified Psychosis, Bipolar Disorder
Interventions
Cognitive and Social Cognitive Training, Personalized Real-Time Intervention for Motivational Enhancement (PRIME) App, Early Psychosis Coordinated Specialty Care
Device · Behavioral · Other
Lead sponsor
University of Minnesota
Other
Eligibility
15 Years to 40 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 12, 2026, 4:56 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Flexible Doses of Extended-release (ER) Paliperidone Compared With Flexible Doses of Quetiapine and Placebo in Patients With Bipolar I Disorder

NCT00309699
View directory record Official record
Conditions
Bipolar Disorder, Mood Disorders
Interventions
Placebo, Quetiapine, Paliperidone ER
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
22
States / cities
Cerritos, California • Garden Grove, California • Oceanside, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2014 · Synced Sep 12, 2026, 4:56 PM EDT
Completed Not applicable Interventional

Multifamily Psychoeducation and Cognitive Remediation for Recent-Onset Psychosis

NCT01196286
View directory record Official record
Conditions
Recent-Onset Psychosis, Schizophrenia, Schizoaffective Disorder, Bipolar Disorder With Psychotic Features, Major Depression With Psychotic Features, Psychotic Disorder Not Otherwise Specified (NOS)
Interventions
Multifamily Group Psychoeducation (MFG), Cognitive Remediation (CR)
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 35 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated May 20, 2020 · Synced Sep 12, 2026, 4:56 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Seroquel Plus Mood Stabilizer in the Maintenance of Bipolar I Disorder

NCT00081380
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Seroquel®, quetiapine fumarate (atypical antipsychotic), lithium (mood stabilizer), divalproex (mood stabilizer)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
710 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
81
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 78 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2008 · Synced Sep 12, 2026, 4:56 PM EDT
Completed Not applicable Interventional Results available

Treatment to Enhance Cognition in Bipolar Disorder

NCT01470781
View directory record Official record
Conditions
Bipolar Disorder, Psychosis
Interventions
BrainWorks, Computer Control
Behavioral
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 50 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Sep 12, 2026, 4:56 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Multi-modal Assessment of Gamma-aminobutyric Acid (GABA) Function in Psychosis

NCT04004416
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Healthy, Psychosis, Schizophreniform Disorders, Schizo Affective Disorder, Major Depression With Psychotic Features
Interventions
Placebo and fMRI, Lorazepam and fMRI
Other · Drug
Lead sponsor
University of Michigan
Other
Eligibility
16 Years to 60 Years
Enrollment
143 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 12, 2026, 4:56 PM EDT
Completed Phase 3 Interventional Results available

Open-label Ziprasidone Study for Psychosis Treatment in Adolescents

NCT00421954
View directory record Official record
Conditions
Schizophreniform Disorder, Schizoaffective Disorder, Psychosis, Depressive Disorder, Major, Bipolar Disorder
Interventions
Ziprasidone
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
13 Years to 17 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Sep 12, 2026, 4:56 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Mitochondrial Dysfunction in the Pathophysiology and Treatment of Bipolar Disorder

NCT00327756
View directory record Official record
Conditions
Bipolar Affective Disorder, Depression
Interventions
Coenzyme Q10
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 22, 2011 · Synced Sep 12, 2026, 4:56 PM EDT
Not listed Phase 4 Interventional

Clozapine Versus Olanzapine as Treatment for Comorbid Psychotic Disorder and Substance Use Disorder

NCT03857581
View directory record Official record
Conditions
Psychosis, Substance Use Disorders
Interventions
Clozapine, Olanzapine
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Evans, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 22, 2020 · Synced Sep 12, 2026, 4:56 PM EDT
Completed Not applicable Interventional Results available

CBTpro: Scaling up CBT for Psychosis Using Simulated Patients and Spoken Language Technologies

NCT05127837
View directory record Official record
Conditions
Psychosis, Schizophrenia, Schizo Affective Disorder, Bipolar Disorder, Depressive Disorder
Interventions
CBTpro
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 100 Years
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
13
States / cities
Los Angeles, California • Morgan Hill, California • San Jose, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 12, 2026, 4:56 PM EDT
Completed Phase 2 Interventional

A Study to Assess the Safety, Tolerability and Efficacy of RG2417 in Bipolar I Depression

NCT00812058
View directory record Official record
Conditions
Bipolar I Depression
Interventions
RG2417, Placebo
Drug
Lead sponsor
Repligen Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
36
States / cities
Birmingham, Alabama • Little Rock, Arkansas • San Diego, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2011 · Synced Sep 12, 2026, 4:56 PM EDT
Completed No phase listed Observational Results available

Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study

NCT01269710
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorder, Not Otherwise Specified, Prodromal Schizophrenia, Mood Disorder, Bipolar Disorder, Major Depressive Disorder, Depressive Disorder, Not Otherwise Specified, Mood Disorder, Not Otherwise Specified, Autism Spectrum Disorder
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
3 Years to 19 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 21, 2013 · Synced Sep 12, 2026, 4:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Families With Substance Use and Psychosis: A Pilot Study

NCT04284813
View directory record Official record
Conditions
Psychosis, Substance Use, Substance Use Disorders, Family, Tobacco Use, Nicotine Use Disorder, Cigarette Smoking, Cannabis, Marijuana, Alcohol Use Disorder, Alcohol, Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Mental Disorder
Interventions
CRAFT-FT
Behavioral
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 11, 2022 · Synced Sep 12, 2026, 4:56 PM EDT
Completed Not applicable Interventional

Academic-Community EPINET (AC-EPINET)

NCT04497857
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders, Major Depression With Psychotic Features, Bipolar Disorder With Psychotic Features
Interventions
Coordinated Specialty Care (CSC)
Other
Lead sponsor
Indiana University
Other
Eligibility
16 Years to 35 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
6
States / cities
Indianapolis, Indiana • New Orleans, Louisiana • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Sep 12, 2026, 4:56 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Smoking Cessation for Veterans With Severe and Persistent Mental Illness

NCT00960375
View directory record Official record
Conditions
Schizoaffective Disorder, Schizophrenia, Affective Psychosis, Bipolar, Affective Disorders, Psychotic
Interventions
BTSCS, StSST
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 75 Years
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 17, 2015 · Synced Sep 12, 2026, 4:56 PM EDT
Completed Phase 3 Interventional Results available

Treatment of Mania Symptoms With Drug Therapy

NCT00183443
View directory record Official record
Conditions
Bipolar Disorder, Schizophrenia
Interventions
Divalproex-extended release (DVP-ER), Lithium, Quetiapine
Drug
Lead sponsor
Palo Alto Veterans Institute for Research
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Sep 12, 2026, 4:56 PM EDT
Completed Phase 2 Interventional

Acute Effectiveness of Additional Drugs to the Standard Treatment of Depression

NCT00001483
View directory record Official record
Conditions
Bipolar Disorder, Depressive Disorder
Interventions
buproprion (Wellbutrin), sertraline (Zoloft), venlafaxine (Effexor)
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 12, 2026, 4:56 PM EDT
Completed No phase listed Observational

Central Nervous System Disease in HIV-infected Children on HAART

NCT00110331
View directory record Official record
Conditions
HIV Infections, Central Nervous System Diseases
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Sep 12, 2026, 4:56 PM EDT
Completed Phase 3 Interventional

Phase III/Seroquel SR Bipolar Depression Monotherapy - US

NCT00422214
View directory record Official record
Conditions
Affective Psychosis, Bipolar, Depression, Bipolar, Manic-Depressive Psychosis, Psychoses, Manic-Depressive
Interventions
Quetiapine fumarate (Seroquel) SR
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
54
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2009 · Synced Sep 12, 2026, 4:56 PM EDT
Completed Phase 4 Interventional

Psychosocial Therapy Plus Maintenance Pharmacotherapy for Treating Bipolar Disorder

NCT00227968
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Interpersonal Social Rhythm Therapy (IPSRT), Clinical Status and Symptom Response Therapy (CSSRT)
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2002
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Sep 12, 2026, 4:56 PM EDT
Completed Not applicable Interventional

Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis

NCT01878513
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Psychotic Disorder Not Otherwise Specified, Severe Bipolar Disorder With Psychotic Features
Interventions
risperidone
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 60 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Aug 26, 2018 · Synced Sep 12, 2026, 4:56 PM EDT
Recruiting No phase listed Observational

Transition Care for FEP

NCT07713849
View directory record Official record
Conditions
Schizoaffective Disorders, Bipolar Disorder With Psychotic Features, Schizophrenia Disorders, Major Depressive Disorder With Psychotic Features, Psychosis NOS
Interventions
Transition Care Team
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 40 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Chicago, Illinois • Harvey, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 12, 2026, 4:56 PM EDT
Completed Phase 3 Interventional

Efficacy & Safety of Seroquel Plus Mood Stabilizer in the Maintenance of Bipolar I Disorder

NCT00107731
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
quetiapine fumarate, lithium, divalproex
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
710 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
36
States / cities
Birmingham, Alabama • Beverly Hills, California • Chula Vista, California + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2009 · Synced Sep 12, 2026, 4:56 PM EDT
Completed No phase listed Observational

Pediatric Bipolar Registry

NCT02360267
View directory record Official record
Conditions
Bipolar Disorder, Depression, Mania, Psychosis
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
6 Years to 17 Years
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2025 · Synced Sep 12, 2026, 4:56 PM EDT